Rising Use of Obesity Drugs Sparks Cost and Access Challenges
Pharmaceutical companies and entrepreneurs are promoting a new payment model where employers subsidize the cash price of obesity medications like Wegovy and Zepbound, allowing employees to access these drugs at lower costs without insurance, potentially reducing overall expenses for both parties.